TE
CYTK icon

Tema ETFs’s Cytokinetics CYTK Stock Holding History

Tema ETFs’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
22,413
+14,251
+175% +$1.02M 0.06% 191
2026
Q1 		$538K Sell
8,162
-5,116
-39% -$325K 0.04% 351
2025
Q4 		$844K Sell
13,278
-8,306
-38% -$517K 0.07% 266
2025
Q3 		$1.19M Sell
21,584
-2,412
-10% -$99.4K 0.1% 229
2025
Q2 		$793K Sell
23,996
-8,592
-26% -$299K 0.21% 119
2025
Q1 		$1.31M Sell
32,588
-14,795
-31% -$680K 0.39% 78
2024
Q4 		$2.23M Buy
+47,383
New +$2.46M 0.93% 33

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tema ETFs's CYTK Position: Q2 2026 in Review

Tema ETFs increased its Cytokinetics (CYTK) stake by 175% in Q2 2026, buying an estimated $1.02M and bringing the position to 22,413 shares worth $1.91M. The position accounts for 0.06% of the portfolio, ranked #191.

Tema ETFs first reported a position in CYTK in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.23M in Q4 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Tema ETFs held 22,413 shares of Cytokinetics worth $1.91M as of Q2 2026.
  • Tema ETFs bought 14,251 Cytokinetics shares in Q2 2026, an estimated $1.02M.
  • Cytokinetics made up 0.06% of Tema ETFs's portfolio in Q2 2026, its #191 holding.
  • Tema ETFs first reported a position in Cytokinetics in Q4 2024 and has held it in 7 quarters since.
  • Tema ETFs's Cytokinetics position peaked at $2.23M in Q4 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Tema ETFs's 13F filing for Q2 2026, filed 10 Jul 2026.